- Initial agreement covers reservation of state-of-the-art cell and gene facility in Morris Plains, U.S.
- HER 2 targeted CAR-M cell therapy is tested in initial trials for the treatment of solid tumors
- Follows last year’s agreements to provide manufacturing capacity for third parties including BioNTech’s Covid vaccine
Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
Under the terms of the initial agreement, the Carisma Therapeutics manufacturing process will be transferred to the Novartis Cell Therapy Site in Morris Plains, U.S, starting in the coming days. Clinical manufacturing is planned to begin in 2023.
“The Global Biotech Cooperations unit of Novartis is fully committed to collaborate with Carisma Therapeutics to bring their CAR-M cell therapy to patients by offering its proven state-of-the art cell and gene production capabilities,” said Anton Gerdenitsch, Head of the Contract Manufacturing Organization at Novartis Technical Operations. “As one of the world’s largest producers of medicines, Novartis can mobilize its manufacturing capacity in an efficient way on multiple fronts.”
This new agreement follows contract manufacturing agreements signed last year such as the agreements with BioNTech, for the filling of the Covid vaccine at the Novartis Technical Operations’ sites in Stein, Switzerland, and in Ljubljana, Slovenia.
Novartis continues to offer its world-class capabilities to other companies to take over manufacturing activities including a variety of technologies such as mRNA production and others. Further specifics will be disclosed when agreements are concluded.
Carisma (www.carismatx.com) is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA.
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.
Global Biotech Cooperations (GBTC) is a contract manufacturing organization powered by the resources and capabilities of Novartis. Our purpose is to help customers manufacture life-changing biotechnological products with our state-of-the-art production facilities.
We’re a team of highly-skilled experts working in innovative, cGMP-compliant sites around the world – building on decades of pharmaceutical and biotechnological manufacturing experience. Find out more at Global Biotech Cooperations | Novartis
Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact email@example.com
# # #
Novartis Media Relations
| Antonio Ligi|
Novartis Global NTO Communications
+44 79 723 36 81 (mobile)
| Puja Kalra|
Novartis Global NTO Communications
+41 79 699 95 98 (mobile)
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
|Samir Shah||+41 61 324 7944||Sloan Simpson||+1 862 778 5052|
|Isabella Zinck||+41 61 324 7188|